European pharma companies warned the European Commission president at a meeting on Tuesday that U.S. tariffs would expedite ...

The Federal Circuit reversed finding sufficient written description. The Federal Circuit explained that the written description requirement pertains only to the claims themselves and the construction ...

European pharma companies warned the EU Commission President that potential U.S. tariffs could accelerate the industry’s move to the United States. The EFPIA calls for regulatory reforms to foster ...

Part of the partners' plan is to use Plex's AI to identify potential new uses for existing treatments that can be used to ...

The FDA has granted accelerated approval to Vanrafia to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.

Leading pharmacy benefit managers are shifting away from lucractive rebates on biologic drugs and toward lower-cost ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novartis AG (NOVN – Research Report), with a ...

U.K.-based Epsilogen has bought Boston biotech TigaTx with the aim of creating “the world’s leading pan-isotype cancer ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF95.00.

Tertiary lymphoid structures (TLS) are increasingly recognized to have roles in cancer. Within tumor microenvironments (TME), TLS can arise as ectopic lymphoid organs containing aggregates of ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

Novartis is thriving with double-digit growth, driven by key drugs in oncology, cardiology, immunology, and neurology. See ...